Index

Abramovitz, M. 21, 35
Ackerman, B. 33
Adams, C. 184
Adams, W. 123
Aghion, P. 13–14, 16
Ahlborn, C. 124, 126, 128, 169
Akman, P. 64, 66, 69
Alchian, A. 101
Alese, F. 50–51, 62–3
Alexander, J. 36
Allen, W. 101
Almeida, A. 94
Amato, G. 172
Amendola, M. 16
Anderman, S. 44, 50, 147
Andrews, C. 189
Angland, J. 48, 73
Apostolopoulos, H. 163
Arendt, P. 1, 6, 23, 47, 54, 56, 57, 62,
64, 65, 66, 112, 113, 115, 122, 141,
143–4, 146–7, 148, 171, 172
Armstrong, M. 121
Arpon, A. 74
Arrow, K. 13, 31–2, 33
Arthur, T. 64
Arthur, W. 19, 20
Audretsch, D. 12
Austrian School 17–18, 39
Ayres, I. 86–7
Baer, W. 158
Bain, J. 9
Bainbridge, D. xvi, xvii
Baker, D. 65
Baker, J. 2, 10, 14, 25, 63, 140
Bakos, Y. 121
Baldwin, W. 15, 100
Balmer, T. 183
Balto, D. 158, 192, 196
Balto, J. 23
Bansal, P. 20
Barnett, J. 33
Barnett, T. 81
Bauer, J. 154, 189
Baumol, W. 9, 11, 12
Bayus, B. 79
Beck, R. 101
Becker, G. 31
Becker, L. xvi
Bellis, J. 67, 175
Bentley, L. xvii, 30
Bernheim, B. 143
Besen, S. 19, 29, 116
Bessen, J. 25, 33, 37
Bishop, S. 5
Blaug, M. 4–5
Bloch, R. 55, 69
Bloom, M. 173
Blumenthal, W. 52, 65
Boccaccio, M. 2, 8, 15, 27, 51, 63, 67,
80, 140
Bohannan, C. 30
Bone, R. 181, 187
Bork, R. 16, 49, 63, 89, 123, 183, 185,
196, 200, 201
Boudin, M. 141
Bourgeois, H. 53
Bowman, W. 83
Boyle, P. 157
Braeutigam, R. 183
Branstetter, L. 37
Brennan, T. 1, 24, 48, 81
Bresnahan, T. 155
Breuvar, C. 201, 202
Breuer, S. 35
Brodley, J. 22, 81, 185
Brunell, R. 24, 50
Brunozza, G. 2, 8, 15, 27, 51, 63, 67,
80, 140
Brynjolfsson, E. 121
Buccicrossi, P. 1–2, 71
Buckley, M. 176

251

Mariateresa Maggiolino - 9781849809634
Downloaded from Elgar Online at 03/28/2019 08:53:17AM
via free access
Intellectual property and antitrust

Budzinsky, O. 24
Burke, A. 87, 101
Burtis, M. 10, 11, 157
Buttigieg, E. 16, 59, 80

Calvani, T. 67, 87–8
Camesasca, P. 5, 124
Candrillo, S. 35
Cantner, U. 23
Carlson, S. 93
Carlton, D. 6, 9, 11, 14, 50, 53, 60, 71, 78, 89, 126, 127, 142, 143, 144, 177
Carrier, M. xvi, 36, 154, 159, 172
Cass, R. 20, 55
Cavanagh, E. 148, 149
Ceccagnoli, M. 98
Chamberlin, E. 4
Chan, K. 98
Chtorovsky, S. 27
Chicago School 5, 70–71, 171
competition
anti-competitive behavior 54–5, 57–8
as-efficient competitor test 61–2
and innovation and monopoly power 12–21
perfect 4–8, 13–14
see also monopoly
 Consumers' surplus
competition law
and IPR equilibrium, EU 175–6
and refusal to license IPRs 154–60
consumer welfare
and IPR judicial and administrative processes 184–8
and isolated predatory innovations 91
and license refusal 168–9
and patent accumulation 92–3
and predatory system innovations 120–28
Cornish, W. xvi, xvii, 176
Correia, E. 64
Cotter, T. 38, 177, 181
Cournot, A. 4, 120
Cowling, K. 90
Crandall, R. 63, 140
Crane, D. 182
Crew, E. 87
Cseres, K. 65
Czapracka, K. 74–5
Damich, E. 27–8
David, C. 126
David, P. 20, 35, 42
Davis, D. 199
Davis, K. 19
Davis, M. 183
Davis, R. 56, 73
Davis, S. 121
Dayagi-Epstein, O. 51, 67
De Sevo, R. 181
De Smet, D. 142
Delrahim, M. 176
Demsetz, H. 9, 33
Denicolò, V. 37, 117
Derzko, N. 183
Devlin, A. 35, 44–5, 120
Dieny, E. 201, 203
Dixit, A. 88, 95
Dolmans, M. 135
dominant firms see monopoly power
Dorffman, N. 15
Dosi, G. 17, 40, 41, 42
Drexl, J. 5, 43, 54, 71
Driscoll, J. 56
Dunford, R. 87
Dusollier, S. 29

Easterbrook, F. xii, 23, 33, 118, 132, 183, 201
Eaton, C. 88
economics
Chicago School see Chicago School
evolutionary 17–18, 39–42
Harvard School 4–11, 23, 64, 65
heterodox 16–21, 39–42
IP administrative procedures 183–4
and IPRs, interpretative limits 25–31
and license refusal 142–5
mainstream economics 31–9, 40
neoclassical 3–7
no economic sense test 61
Ordoliberalism 48, 64, 65, 66, 69
Economides, N. 116, 120, 148, 149, 171
Edgeworth, F. 4
Edlin, R. 61
Edquist, C. 12
Ehlermann, C. 64
Eilmansberger, T. 57, 65
Eisenberg, R. 37, 94, 97, 100
Eklof, D. 83, 84
Elhauge, E. 48, 61, 62, 146, 183, 193, 195, 200
Ellig, J. 17
Elzinga, K. 130
entry barriers 8, 9, 89, 92–4, 125–6
Epstein, R. xvi
Erramouspe, M. 36
Etzkowitz, H. 87
EU
Charter of Fundamental Rights, Article 47 190
Commission’s Enforcement Priorities in Applying Article 82 55, 147
competition law and invalid patents 113
competition law and IPR equilibrium 175–6
dominant firms’ infringement actions 197–8
dominant firms’ IP administrative procedures 201–3
and false-positive issues 171–2
‘innovation’s incentive’ test and Microsoft IV 163–5
leveraging monopoly theory 122
license refusal and ‘new product’ and ‘new market’ criteria 160–63
‘limitation to technical development’ criterion and Microsoft V 166–8, 170
Merger Regulation 75
patent and copyright laws 26–8, 38, 39
patent procurement, legal approaches to 101–2
pharmaceutical patents 104
predatory system innovations see predatory system innovations
predatory system innovations and objective justification 135–6
Umbrella Regulation 75
see also competition; IPR headings
EU cases
AstraZeneca 54, 69, 103, 104–5, 113, 197, 198, 201–3
BB/I/Boosey and Hawkes 197
Boehringer 201
British Airways v. Commission 70
Cement 190
Centrafarm v. Sterling Drug 174
Centrafarm v. Winthrop 174
CICRA 117, 160
Cimenteries 190
Commercial Solvents Corp v. Commission 65
Compagnie Maritime Belge 190
Continental Can 59
Decca Navigator System 133, 197
Deutsche Grammophon xii, 74, 102
DSR-Senator Lines GmbH v. Commission 69
Football World Cup 58
French-West African ship-owners’ Committees 190
Hag II 174
Hauer v. Land Rheinland Pfalz 175
Hilti AG v. Commission 74, 135, 190–91
Hoffmann-La Roche v. Commission 47, 54, 55
Hugin Cash Registers Ltd v. Commission 65
IBM Settlement 133–4, 162
ITT Promedia NV v. Commission 93, 191, 197–8
Intellectual property and antitrust

Ladbroke (Tiercé Ladbroke SA v. Commission) 162
Maxicar v. Régie nationale des usines Renault 117
Michelin cases 47, 54
Microsoft cases 70, 75, 117, 133–8, 158, 161–7, 176
NV Algemene Transport v. Netherlands Inland Revenue Administration 67
Oscar Bronnar 146, 150, 151, 162, 163, 164, 176
Parke, Davis and Co. v. Centrafarm xii, 102, 175
Perindopril (Servier) 201
Radio Télévis Eireann v. Commission 147–8
Sirena Srl v. Eda Srl and Others 74, 102, 174
Tetra Pak cases 57, 74, 109, 110, 135
Van Zuylen Frères v. Hag AG 174
Volvo AB v. Erik Veng (UK) Ltd. 26, 117, 160
EU, TFEU, Article 102 and US, Sherman Act, Section 2
apparent content 54–9
appropriability tools with different perspectives 82–4
as-efficient competitor test 61–2
background policy choices and monopolies 46–54
and brand proliferation 78–9
dominant firms, past and present objectives for dealing with 63–71
dominant position abuse 191
and fraudulent procurement of patents 103–5
and legal protection of innovation 77–82
and monopoly power 54–9
new market criteria 167
no economic sense test (but for test) 61
profit sacrifice test 59–61
and risk assessment 56–7
and separate products requirement 131–2
unlawful behavior, standards for detecting 59–63, 72–6
Evans, D. 20, 23, 54, 120, 124, 126, 127, 128, 135, 178
exclusionary conduct 89, 109–12, 143–4, 183–6
Ezrachi, A. 51, 52
Fagerber, J. 12
Farrell, J. 11, 19, 61, 88, 116, 120, 187
Feldman, R. 124, 126
Fellmeth, R. 87
First, H. 48, 53, 118–20, 173
Fischel, D. 189, 196
Fisher, F. 9, 124, 125, 127, 130
Fisher, W. 30
Fitzpatrick, D. 182, 194
Flynn, J. 64, 81, 87, 113, 173
Forrester, I. 29, 64, 67, 161, 162, 176
Foss, N. 17
Fox, E. 64, 65, 69, 71, 72, 149
Friedman, A. 128
Frischmann, B. 141
Frost, G. 87
Fudenberg, D. 97
Furse, M. 57
Gal, M. 65
Gallini, N. 37
Gambrell, J. 157, 159
Gandal, N. 20, 137
Garza, D. 71
Gavil, A. xv, xvi, 48, 53, 54, 59, 62, 63, 140, 173
Gaynor, D. 120
Genevaz, S. 159
Gerardin, D. 169
Gerber, D. 1, 22, 65, 69, 71, 74, 143, 144
Geroski, P. 15, 44, 83
Ghidini, G. xvi
Giff ord, D. 47, 64, 157
Gordon, R. xv, 9, 12, 14, 37, 85, 88, 92, 95, 97, 98, 100, 113, 116, 120, 141
Ginsburg, D. 67
Ginsburg, J. xvii, 27, 29
Glader, M. 21
Glazer, K. 162, 163
Goldstein, P. 83
Index

Gordon, W. xxvii, 34, 37
Gormsen, L. Lovdahl 5, 52, 54, 64, 65, 68, 71, 74, 77, 78, 150
Gould, J. 186
Grady, M. 36
Graf, T. 135
Green, J. 38
Gregory, J. 141
Gruca, T. 88
Gual, J. 14–15
Gunther, J. 201, 202

Hall, B. 37, 96–7
Ham, R. 97
Hamilton, W. xvii
Handke, C. 31
Handler, M. 181
Harhoff, D. 34
Harris, G. 184
Hart, D. 21
Hart, R. 176
Hatch, O. 34
Haven, J. 15
Hay, D. 78–9
Hayek, F. 18
Heiner, D. 132
Heller, M. 37, 94, 97, 100
Hettinger, E. xvii
Heyer, K. 50, 78, 172
Higgins, R. 88
Hoerner, R. 191–2
Hohfeld, W. xvi
Hotelling, H. 88
Hovenkamp, H. xv, 1–3, 6, 10, 13, 28, 30, 33, 38, 47, 54–66, 72, 77, 83, 84, 86, 89, 109–15, 122, 128, 132, 141–8, 156, 171, 172, 174, 185, 188, 196
Howarth, D. 135
Hughes, J. xvii, xviii, 28–9
Hunt, R. 25, 37, 94
Hurt, R. 35
Hurwitz, J. 132, 184, 185, 187, 195, 199, 200, 201
Hylton, K. 20, 55, 143, 146

Immordino, G. 53
innovation
boost and restriction (EU/US comparison) 177–9

and competition, and monopoly power 12–21
follow-on, prevention of 98–9
incentives 99–100, 163–5
isolated predatory 90–92
legal protection of 77–82
predatory system see predatory system innovations
and strong patent rights 36–7
IPR judicial and administrative processes 180–205
and consumer welfare 184–5, 186–8
convergent EU and US approaches 204–5
defendants’ costs 185–7
dominant firms’ infringement actions (EU) 197–8
dominant firms’ infringement actions (US) 191–7
dominant firms’ IP administrative procedures (EU) 201–3
dominant firms’ IP administrative procedures (US) 198–201
economic perspective of IP administrative procedures 183–4
and exclusionary practices 183–6
infringement actions 184–8
invalid patents 194
legal perspective and rights of petitioning 188–91
and misleading and false information 196
‘no economic sense’ (‘but for’) 61, 188
pharmaceutical industry, Orange Book entry and supplementary protection certificate (SPC) 180–81, 183, 199, 200–203
and reputation of predatory practices 185
strategic infringement action 187
IPR, license refusal 141–79
after-the-fact, case-by-case conflict 141–2
and competition law (US) 154–60
and compulsory licensing 149
and consumer welfare loss 168–9
and duty to deal 164
economic thinking 142–5
EU/US comparisons 142, 145–54, 168–70, 174–9
and exclusionary practices 143–4
and exploitative practices 143
false-positive issue 171–3, 178
and innovation boost and restriction (EU/US comparison) 177–9
‘innovation’s incentives’ test (EU) 163–5
IP culture, role of (EU/US comparison) 174–7
jurisdictional and cultural issues (EU/US comparison) 142, 168–70
and leveraging monopoly theory 144, 153
‘limitation to technical development’ criterion (EU) 166–8
and monopoly profits 149
‘new product’ and ‘new market’ criteria (EU) 160–63
and patent and copyright misuse 159–60, 174
and secondary markets 163
see also licensing
IPR ownership 85–114
and brand proliferation 78–9, 93
compulsory licensing 106–8, 114
effects-based and form-based approaches, differences between 51–2
entry deterrence strategies 89
and exclusionary conduct 89, 109–12
follow-on innovation, prevention of 98–9
and innovation incentives 99–100, 163–5
internally developed patents and EU/US convergence 112–14
invalid patents and competition law 113
isolated predatory innovations 90–92
licensing costs and lock-ups 93–4
and market spatial analysis 88, 95
and monopolists’ grantback agreements 111
non-use of patents 105–8
patents see patents
pharmaceutical patents 104
and predatory pricing 87–8
and profitability 96–7
and R&D investment 95
raising rivals’ costs theory 89–90, 149
sleeping patent strategies 94–100, 114
and strategic advantage 88–9
suppressed patents 100–101, 107–8
and tech-transfer agreements 96–7

Jacobs, J. 19
Jacobs, M. 1, 11, 24, 44–5
Jaffe, A. 37, 96
Janis, M. 83, 86, 109, 110, 132, 143, 148, 156, 174, 196
Jebsen, P. 49, 67
Johnson, W. 30
Joliet, R. 58–9
Jones, A. 1, 24, 172
Jorde, T. 12, 36
Joskow, P. 10
Kallay, D. 18, 39
Kanter, D. 169
Kaplow, L. 93, 124
Karp, L. 97–8, 99
Kate, A. 64
Katz, A. 177
Katz, M. xvi, 19, 23, 50, 88, 116, 120
Kaufman, B. 87
Kaufmann, J. 11
Kauper, T. 47, 48
Kavanagh, J. 11, 74, 75
Kaysen, C. xvi, 9, 66, 92, 94
Kellezi, P. 118, 139
Kieff, F. 32
Kintner, E. 189
Kirzner, I. 4, 17, 18
Kitch, E. 34, 37, 44, 95
Klein, C. 181, 182, 187
Klein, J. 20
Klein, P. 10
Klemperer, P. 37, 86–7
Knight, F. 4
Kobak, J. 67, 169, 175, 189–90, 193, 194, 205
Kobayashi, B. 10–11, 120, 123, 127, 157
Kolasky, W. 48
Kolay, S. 123
Index

Kolstad, O. 28, 83
Korah, V. 146, 162, 171
Kovacic, W. 3, 11, 25, 27, 63, 73, 132, 140, 173
Kroes, N. 70
Krouse, B. and C. 187
Krueger, A. 7
Kudrle, R. 47, 64
Kukkonen, C. 15
Kwall, R. xvii
Kwok, Y. 98

Lachmann, L. 18
Laffont, J. 121
Lancaster, K. 70
Lande, R. 63, 66, 71
Landers, A. 97
Landes, W. 6, 30, 31, 182, 186
Langer, J. 57, 118, 122, 125
Langlois, R. 17, 37, 124, 143, 144, 145
Lao, M. 55, 141, 149, 191, 192, 193, 195
Larner, R. 9
Laudati, L. 64
Lee, K. 114
Lee, T. 34
Lehmann, M. xvii
Leibenstein, H. 7
Leslie, C. 86, 194
Lêvéque, F. 164, 168, 169
Levin, R. 15, 16, 18, 37
Levine, L. 15, 101
Levy, R. 20
Lewin, P. xvii–xviii
Lianos, I. 52
licensing
  compulsory 106–8, 114, 149
  costs and lock-ups 93–4
  refusal see IPR, license refusal
Liebowitz, S. 19, 20, 130
Lin, D. 17
Lipsey, R. 88
Lipsky, A. 141
Liu, J. 30
Llewelyn, D. xvi, xvii, 176
Loewenthal, P. 75
Lofaro, A. 125
Lopatka, J. 14, 19–20, 130
Lowe, P. 70, 75, 83
Lundvall, B. 12
McAfee, P. 123, 182
McDonald, J. 65, 169
McDonough, J. 94
McFetridge, D. 36
McGowan, D. 20, 141, 191
Machlup, F. 12–13
Machovec, F. 4
Mackaay, E. 30
Mackie-Mason, J. 172
McMahon, K. 135
McNulty, P. 4, 6
Malerba, F. 11, 16, 21, 23
Mannes, R. 92
Marengo, G. 67
Marengo, L. 40, 41, 42
Margolis, S. 19, 20, 130
markets
  new market criteria 167
  and monopoly power 11–13, 53–8
  'new product' and 'new market' criteria (EU) 160–63
  secondary 115–16, 120, 123–4, 125, 163
  spatial analysis, and IPR ownership 88, 95
Marshall, A. 16, 66
Martin, S. 71
Maskin, E. 37
Mason, E. 9
Matutes, C. 116, 125, 127
May, J. 2, 63–4
Mazzoleni, R. 29, 41
Meehan, J. 9
Meinberg, H. 162
Meinhardt, P. 101
Melamed, D. 59, 159
Ménière, Y. 168
Merges, R. xii, 26–7, 30, 36, 41, 43–4, 97, 187
Merrill, T. xvi
Mertikopoulou, V. 68
Meurer, M. 33, 187
Meyer, D. 200
Michelman, F. xviii
Miller, J. 183
Millon, D. 173

Mariateresa Maggiolino - 9781849809634
Downloaded from Elgar Online at 03/28/2019 08:53:17AM
via free access
Mills, D. 130
Minda, G. 70–71, 189, 200
monopoly power
and competition see competition concerns over 3–16
dominant firms, past and present objectives for dealing with 63–71
grantback agreements 111
and heterodox economics 16–21
and infringement actions 191–8
and innovation and competition 12–21
and IP administrative procedures 198–203
leveraging monopoly theory 121–4, 125, 139, 153
and market power 11–13, 53–8
multi-product monopolists and incompatibility via innovation 115–19, 122, 125
and neoclassical economics 3–7
and path dependency 19–21
policy choices in antitrust world 22–5
and predatory system see predatory system innovations
profits, and IPR, license refusal 149
profits, and predatory system innovations 124–5, 126, 127
Montagnani, M. 132
Monti, G. 11, 70
Monti, M. 2, 70, 75
Moore, A. xvi, xvii
Morgenstern, O. 10
Möschel, W. 65
Moss, S. 5
Motta, M. 5, 7, 50, 89, 94, 125
Mueller, D. 90
Muris, T. 1, 182
Myers, G. 186, 187, 205
Nalebuff, B. 118, 120, 125
Nelson, R. 16, 17, 18, 26–7, 29, 30, 31, 41, 43–4, 97, 98, 180
Netanel, N. xviii, 27
Newberg, J. 83
Newbery, D. 85, 97, 98, 100, 113
Niels, G. 64, 74, 75
Noah, L. 181, 183, 200
Norhaus, W. 37
O’Donnell, S. 194, 196
O’Donoghue, R. 48, 53, 57, 58, 60, 61, 62, 65, 66, 72, 134–5, 145, 169, 188
Oettinger, N. 157, 159
Ordover, J. 7, 12, 32, 36, 59, 84, 90, 91, 92, 118, 121, 143, 155
Owen, B. 183
Padilla, J. 48, 53, 57, 58, 60, 61, 62, 65, 66, 72, 120, 124, 126, 128, 134–5, 145, 169, 188
Page, W. 3, 19–20, 64, 130
Palmer, T. xvii
Palomeras, N. 15
Pate, R. 24, 55, 58, 59, 82, 157
patents
accumulation 92–4
and copyright laws 26–8, 36, 38–9
and copyright misuse 159–60, 174
costs of 34–6, 86–7
fraudulent procurement 103–5
innovation and strong patent rights 36–7
internally developed and EU/US convergence 112–14
invalid 113, 194
non-use of 105–8
pre-emption and monopoly power 97–8
procurement, legal approaches to 101–2
sales and licenses, and IPR ownership 108–12
sleeping patent strategies 94–100, 114
suppressed 100–101, 107–8
see also IPR headings
Patry, W. 30
Patterson, M. 59
Paulis, E. 83
Pautler, P. 183
Peeperkorn, L. 83
Peltzman, S. 10
Peritz, R. 11, 63, 64, 72, 84, 136
Perloff, J. 6, 9, 89, 98, 99
Perrine, J. 183
Index 259

pharmaceutical industry 104, 180–81, 183, 199, 200–203
Piraino, T. 125
Pitofsky, R. 14, 23, 59, 66, 142, 157, 159
Plant, A. 35
Polanyi, M. 40
Polo, M. 53, 128
Ponsoldt, J. 126
Posner, R. 1, 6, 7, 10, 30, 31, 33, 35, 53, 61, 62, 96, 123, 185
predatory system innovations 115–40
and consumer welfare 120–28
EU approach 133–8
leveraging monopoly theory 121–4, 125–6, 136, 139
and monopoly profits 124–5, 126, 127
multi-product monopolists and incompatibility via innovation 115–19, 122, 125
and net plus standard 128–32, 134, 138–40
and objective justification 135–6
primary market defense 126
refusal-to-deal cases, links between 134
and rivals’ entry deterrence 125–6
and secondary markets 115–16, 120, 123–4, 125
and technological tying 117–18, 120–26, 128, 131–2, 135–8
US/EU comparisons 138–40
profit sacrifice test 59–61
Putsis, W. 79
Radin, M. 28
Rahnasto, I. xvi
Raskind, L. 29
Rasmussen, E. 143
Regibeau, P. 116, 125, 127
Reinganum, J. 36, 97, 98
Reitzig, M. 94
Rey, P. 115, 118, 120, 124–5, 144
Reynolds, G. 36
Reznick, R. 194
Ridyard, D. 125, 169
Riordan, M. 120, 185
Ritter, C. 168, 171–2, 176
Robbins, L. 31
Robinson, J. 4
Robledo, J. 185
Roeder, M. xvi
Röller, L. 70
Romaine, R. 130, 164
Rommer, P. 32
Rose, M. 27
Ross, D. xv, 7, 8, 9, 14, 36, 49, 89, 95, 100
Rossman, J. 99
Rousseva, E. 56, 57, 66, 69, 75, 79, 137, 151, 152, 153, 164, 166
Rubinfeld, D. 3, 15, 92, 127, 130
Sakakibara, M. 37
Salant, S. 97
Salinger, M. 120, 123, 127
Saloner, G. 7, 20, 92, 116, 118, 143
Salop, S. 10, 11, 59, 87, 89, 92, 115–16, 120, 130, 143, 144, 164, 182, 185
Sampsung, X. 41
Samuelson, P. 27, 31, 35
Sanders, B. 99, 101
Sanfilippo, L. 57
Sankaran, S. 92
Saunders, K. 15, 101
Schanzenbach, M. 20
Schauer, F. 191
Scheffman, D. 87, 88, 185
Schelling, T. 89
Scherer, F. xv, 7, 8, 9, 14, 16, 30, 34, 35, 37, 49, 78, 85–6, 89, 93, 95, 100, 131, 133, 185
Schlesinger, A. 65
Schmalensee, R. 4, 20, 23, 78, 93, 123, 130, 155, 178
Schmookler, J. 12
Schuchman, R. 35
Schumpeter, J. 12, 16, 17, 24, 34, 39, 53
Schwartz, L. 66
Scotchmer, S. 38
Scott, J. 15
Screpanti, E. 3, 4
Shaffer, G. 123
Shapiro, C. 19, 27, 35, 37, 92, 98, 116, 141
Shavell, S. 35, 186
Shelanski, H. 23, 50
Intellectual property and antitrust

Sher, D. 75, 77
Sherman, B. xvii, 30
Shughart, W. 70, 182
Sibarium, C. 67
Sidak, J. 120, 128, 132
Silbey, J. 27
Simmons, I. 98
Simmons Neveu, D. 184, 187
Sinclair, D. 65
Smith, D. 36
Smith, N. 86
Sobel, G. 87
Solow, R. 21
Soma, J. 19
Spence, A. 89
Stefanadis, C. 126, 127
Stehmann, O. 70
Steinhauer, E. 181, 199
Steinman, D. 182
Stemple, D. 94
Stever, S. 30
Stevens, R. 49, 67
Stigler, G. 4, 9, 10, 13, 123
Stiglitz, J. 11, 13
Stoepelwerth, A. 159
Strand, O. 29
Stratakis, A. 122, 169, 178
Sterkers, S. 120
Sudharshan, D. 88
Sufrin, B. 1
Sullivan, E. 65
Sullivan, J. 47
Sullivan, L. 24, 67, 71, 172
Sunder, M. 27
Sunshine, S. 12, 98
Symeonides, G. 15
Szulanski, G. 40

technological tying 117–18, 120–26, 128, 131–2, 135–8

see also predatory system innovations

Teece, D. 12, 14, 34, 36, 92, 121, 155
Teixeira, A. 94
Tellis, G. 120
Temple Lang, J. 25–6, 48, 58, 168–9
Thorelli, H. 64
Tirel, J. 9, 13, 115, 118, 120, 121, 124–5, 144
Tom, W. 12, 83

Torremans, P. 30
Tullock, G. 7
Turner, D. xvi, 9, 23, 66, 92, 94

Ullrich, H. 2, 33
unlawful behavior, standards for detecting 59–63, 72–6

US

Clayton Act xiii, 124, 174
competition law and invalid patents 113
competition law and refusal to license IPRs 154–60
compulsory licensing 114
Constitution, First Amendment 188–90, 191–3, 195, 196–7
dominant firms’ infringement actions 191–7
dominant firms’ IP administrative procedures 198–201
and false-positive issues 171–2
Federal Food, Drug, and Cosmetic Act (FDCA) 180
Hatch-Waxman Act 180–81, 199
leveraging monopoly theory 121–2
net plus standard, and predatory system innovations 128–32, 134, 138–40
Noerr-Pennington doctrine 102, 103, 189–90, 193, 195–7, 200–201
Patent Act 26, 38, 106, 156, 159–60
patent and copyright laws 26–8, 36, 38–9
patent procurement, legal approaches to 101–2
pharmaceutical patents 104
predatory system innovations see predatory system innovations
Sherman Act 124, 131–2, 172–3
Sherman Act, Section 2 see EU, TFEU, Article 102 and US, Sherman Act, Section 2
sleeping patents, lack of prosecution for 114

US cases

A.A. Poultry Farms v. Rose Acre Farms 72
ADISAT v. Associated Press 55
Agron v. Lin 104
Aldridge v. Microsoft Corp. 150
<table>
<thead>
<tr>
<th>Index</th>
<th>261</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allied Research Products v. Heathbath Corp.</td>
<td>106</td>
</tr>
<tr>
<td>Alling v. Universal Mfg. Corp.</td>
<td>112</td>
</tr>
<tr>
<td>American Council of Certified Podiatric Physicians v. American Board of Podiatric Surgery</td>
<td>55</td>
</tr>
<tr>
<td>Arcade v. Minn. Mining &amp; Mfg. Co.</td>
<td>104</td>
</tr>
<tr>
<td>Armstrong Surgical Center v. Armstrong County Memorial Hospital</td>
<td>196</td>
</tr>
<tr>
<td>Aspen Skiing Co. v. Aspen Highlands Skiing Corp.</td>
<td>72, 149, 151, 164</td>
</tr>
<tr>
<td>Associated Press v. United States</td>
<td>147</td>
</tr>
<tr>
<td>Atari Games Corp. v. Nintendo of Am.</td>
<td>83, 156</td>
</tr>
<tr>
<td>Barry Wright Corp. v. ITT Grinnell Corp.</td>
<td>73</td>
</tr>
<tr>
<td>BellSouth Advertising v. Donnelley Information</td>
<td>154</td>
</tr>
<tr>
<td>Berkey Photo v. Eastman Kodak</td>
<td>101, 102, 122, 128, 155, 157–8, 159, 160, 168</td>
</tr>
<tr>
<td>In re Biovail Corp.</td>
<td>110, 111, 199</td>
</tr>
<tr>
<td>In re Borden, Inc.</td>
<td>79</td>
</tr>
<tr>
<td>Borden v. FTC 73</td>
<td></td>
</tr>
<tr>
<td>Brunswick Corp. v. Pueblo Bowl-O-Mat</td>
<td>146</td>
</tr>
<tr>
<td>In re Buspirone Patent Litig.</td>
<td>200–201</td>
</tr>
<tr>
<td>Caldera v. Microsoft Corp.</td>
<td>131</td>
</tr>
<tr>
<td>California Computer Products v. IBM</td>
<td>57, 128–9</td>
</tr>
<tr>
<td>California Eastern Laboratories v. Gould</td>
<td>104</td>
</tr>
<tr>
<td>California Motor Transport Co. v. Trucking Unlimited</td>
<td>93, 189, 192, 195, 196, 198</td>
</tr>
<tr>
<td>Car-Fresher Corp. v. S.C. Johnson &amp; Son</td>
<td>39</td>
</tr>
<tr>
<td>Carbice Corp. of America Patent Development Corp.</td>
<td>123</td>
</tr>
<tr>
<td>In re Cardizem CD Antitrust Litig.</td>
<td>199</td>
</tr>
<tr>
<td>Cheminor Drugs Ltd. v. Ethyl Corp.</td>
<td>196–7</td>
</tr>
<tr>
<td>Clipper Express v. Rocky Mountains Motor Tariff Bureau</td>
<td>193, 195</td>
</tr>
<tr>
<td>Colorado Interstate Gas Co. v. Natural Gas Pipeline</td>
<td>56</td>
</tr>
<tr>
<td>Continental Paper Bag Co.</td>
<td>105–6, 107</td>
</tr>
<tr>
<td>Continental T.V. v. GTE Sylvania</td>
<td>146</td>
</tr>
<tr>
<td>C.R. Bard v. M3 Systems</td>
<td>129–30</td>
</tr>
<tr>
<td>Credit Suisse Securities v. Billing</td>
<td>146, 156</td>
</tr>
<tr>
<td>Crucible v. Stora Kopparbergs Bergslags AB</td>
<td>87</td>
</tr>
<tr>
<td>Dawson Chemical Co. v. Rohm &amp; Haas Co.</td>
<td>106</td>
</tr>
<tr>
<td>Dippin’ Dots v. Mosey</td>
<td>103</td>
</tr>
<tr>
<td>Dorsey Harvester Revolving Rake Co. v. Marsh</td>
<td>106</td>
</tr>
<tr>
<td>eBay Inc. v. Mercexchange LLC</td>
<td>174</td>
</tr>
<tr>
<td>Electric Smelting &amp; Aluminum Co. v. Carborundum Co.</td>
<td>105</td>
</tr>
<tr>
<td>In re Elevator Antitrust litig.</td>
<td>149</td>
</tr>
<tr>
<td>FMC Corp. v. Manitowoc Co.</td>
<td>103–4</td>
</tr>
<tr>
<td>FTC Intel Corp.</td>
<td>158, 159</td>
</tr>
<tr>
<td>In re General Foods Corp.</td>
<td>79</td>
</tr>
<tr>
<td>Goldstein v. California</td>
<td>29</td>
</tr>
<tr>
<td>Grant v. Raymond</td>
<td>29</td>
</tr>
<tr>
<td>Great Lakes Chem. Corp.</td>
<td>87</td>
</tr>
<tr>
<td>Grip-Pak v. Illinois Tool Works</td>
<td>193</td>
</tr>
<tr>
<td>Handguards v. Ethicon</td>
<td>193, 194–5, 196, 197</td>
</tr>
<tr>
<td>Hartford-Empire Co. v. United States</td>
<td>107–8</td>
</tr>
<tr>
<td>In re IBM Peripheral EDP Devices Antitrust Litig.</td>
<td>129</td>
</tr>
<tr>
<td>ILC Peripherals Leasing Corp. v. IBM</td>
<td>129</td>
</tr>
<tr>
<td>Illinois Tool Works v. Independent Ink</td>
<td>156, 157, 159</td>
</tr>
<tr>
<td>Image Technical Servs. v. Eastman Kodak</td>
<td>117, 157</td>
</tr>
<tr>
<td>Intergraph Corp. v. Intel Corp.</td>
<td>101–2, 150, 154</td>
</tr>
<tr>
<td>International Salt Co. v. United States</td>
<td>124</td>
</tr>
<tr>
<td>Kearns v. Chrysler Corp.</td>
<td>106</td>
</tr>
<tr>
<td>In re Kellogg Co.</td>
<td>79</td>
</tr>
<tr>
<td>Kobe, Inc. v. Dempsey Pump Co.</td>
<td>111</td>
</tr>
<tr>
<td>KSR Intern. Co. v. Teleflex</td>
<td>30</td>
</tr>
</tbody>
</table>
Intellectual property and antitrust

LePage’s Inc. v. 3M 47, 69, 73
McDonald v. Johnson & Johnson 112
Mazer v. Stein 28–9
MCI Communic. Corp. v. AT&T 73
Medimmune, v. Genentech 102
Menorex Corp. v. IBM 129
Mercoid Corp. v. Mid-Continent Investment Co. 123
Microsoft cases 55, 68, 73, 87, 118–20, 127, 130–31, 158, 173
In re Microsoft corp. antitrust litig. 155, 158
Miller Insituform 154
Motion Picture Patents Co. v. Universal Film Mfg. Co. 106, 123
Nichols v. SmithKline Beecham Corp. 199
Nobelpharma AB v. Implant Innovations 194, 196
Olympia Equip. Leasing Co. v. W. Union Tel.Co. 57, 147, 149
OpenLCR.com v. Rates Tech. 104
Organon Inc. v. Mylan Pharmas. 200–201
Ortho Diagnostic System v. Abbott Laboratories 73
Otter Tail Power Co. v. United States 192
Professional Real Estate Investors (PREI) 191–3, 196, 198, 199–200
Rambus v. FTC 68
In re Relafen Antitrust Litig. 199
In re Remeron Antitrust Litig. 199
Schor v. Abbott Laboratories 146, 159
SCM Corp. v. Xerox Corp. 110–11, 154
Sega Enterprise v. Accolade 39
Sony Computer Entertainment v. Connectix Corp. 39
Special Equipment Co. v. Coe 106–7
Spectrum Sports v. McQuillan 55
Standard Oil v. United States 47
Stop & Shop Supermarket Co. v. SmithKline Beecham Corp. 199
Taylor Publishing Co v. Jostens 57
Teletronics Proprietary v. Medtronic 87
Telex Corp v. IBM 117, 129, 132
Tops Markets v. Quality Markets 56
Transamerica Computer Company v. IBM 57
Trinko 50, 57, 72, 121–2, 146, 147, 148–9, 150, 152, 154, 155, 156–7, 159
United Asset Coverage v. Avaya 159
United States v. Addystone Pipe & Steel Co. 72
United States v. Aluminum Co. of Am. 8, 65, 72, 95, 101
United States v. American Bell Telephone Co. 108
United States v AT&T 87
United States v. Colgate & Co. 147
United States v. Dentsply Int’l 57, 69
United States v. E.I. du Pont de Nemours & Co. xii, 55
United States v. General Electric 111
United States v. Griffith 122
United States v. Grinnell Corp. 47, 101
United States v. Loew’s, Inc. xii
United States v. Paramount Pictures 29
United States v. Topco 65, 146
United States v. United Shoe Machinery Corp. 87
Unitherm Food Systems v. Swift-Eckrich 103, 194
In re Visa Check/Mastermoney Antitrust Litig. 199
Walker Process Equip. v. Food Machinery & Chemical Corp. 103, 104, 193–5, 196, 197, 201, 202
Wallace v. IBM 32, 95
Western Parcel Express v. United Parcel Service of America 56
Xerox 117, 155–6, 157, 159, 160, 170, 175, 177
Zacchini v. Scripps-Howard Broadcasting Co. 29
Index

Van Bael, I. 67, 175
Van Cayseele, P. 3, 15, 64
Van den Bergh, R. 3, 5, 64, 72, 124
van Ypersele, T. 35
Venit, J. 65
Verspagen, B. 21
Vezzoso, S. 41, 165
Vickers, J. 17, 57, 60, 97
Viscusi, W. 5
Vogelzang, P. 57
von der Groeben, H. 67
von Hippel, E. 187
von Mises, L. 18
Von Neumann, J. 10
von Weizsacker, C. 33
Vossestein, A. 190
Waldman, M. 126, 127, 143
Walker, M. 5
Watt, R. 31
Weber Waller, S. 141–2
Weeds, H. 99, 100
Weinreb, L. 31
Werden, G. 20, 55, 59, 141, 144
Whinston, M. 123, 125, 127, 143
Whish, R. 48, 51, 57, 58, 63, 74
White, L. 116, 182
Williamson, O. xv, 10, 185
Willig, R. 59, 90, 91, 121, 155
Wilson, T. 88
Winston, C. 63, 140
Winter, R. 183
Winter, S. 17, 24, 33
Wolman, A. 192, 196
Wood, D. 48
Yee, W. 87
Yellen, J. 123
Yen, A. xvii
Zamagni, S. 3, 4
Ziedonis, R. 37, 96–7